Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,946,791
  • Shares Outstanding, K 50,580
  • Annual Sales, $ 2,610 K
  • Annual Income, $ -302,140 K
  • 36-Month Beta 2.26
  • Price/Sales 59.45
  • Price/Cash Flow N/A
  • Price/Book 4.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.79
  • Number of Estimates 5
  • High Estimate -1.72
  • Low Estimate -1.86
  • Prior Year 0.62
  • Growth Rate Est. (year over year) -388.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.51 +25.26%
on 01/30/19
63.24 -7.87%
on 02/20/19
+4.92 (+9.22%)
since 01/18/19
3-Month
37.44 +55.61%
on 12/24/18
63.24 -7.87%
on 02/20/19
+4.63 (+8.63%)
since 11/21/18
52-Week
37.44 +55.61%
on 12/24/18
90.98 -35.96%
on 09/25/18
+11.95 (+25.80%)
since 02/21/18

Most Recent Stories

More News
Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients

RARE : 58.26 (-3.75%)
Report: Exploring Fundamental Drivers Behind Canopy Growth, Adobe, Ultragenyx Pharmaceutical, Humana, Ship Finance International, and NexGen Energy -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC),...

HUM : 307.56 (-0.43%)
RARE : 58.26 (-3.75%)
ADBE : 257.76 (-0.13%)
SFL : 12.36 (-1.04%)
NXGEF : 2.4274 (+4.02%)
NXE : 1.75 (unch)
CGC : 45.04 (-2.66%)
Ultragenyx Pharm Rises 4.58% on Heavy Volume: Watch For Potential Pullback

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $59.41 to a high of $62.94. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high...

RARE : 58.26 (-3.75%)
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4

Ultragenyx (RARE) loss narrower than expected and sales beat estimates in the fourth quarter of 2018.

BAYRY : 19.1650 (-1.21%)
CELG : 88.65 (-1.94%)
RARE : 58.26 (-3.75%)
BDSI : 4.73 (-0.63%)
Ultragenyx: 4Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $87.8 million in its fourth quarter.

RARE : 58.26 (-3.75%)
Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results...

RARE : 58.26 (-3.75%)
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019...

RARE : 58.26 (-3.75%)
Ultragenyx Pharm Shares Up 25.5% Since SmarTrend's Buy Recommendation (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on January 8th, 2019 at $44.98. In approximately 1 month, Ultragenyx Pharm has returned 25.46% as of today's recent price of $56.43.

RARE : 58.26 (-3.75%)
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita(R) (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa...

RARE : 58.26 (-3.75%)
Will Ultragenyx (RARE) Report Negative Q4 Earnings? What You Should Know

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE : 58.26 (-3.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 62.99
1st Resistance Point 60.63
Last Price 58.26
1st Support Level 56.05
2nd Support Level 53.83

See More

52-Week High 90.98
Fibonacci 61.8% 70.53
Fibonacci 50% 64.21
Last Price 58.26
Fibonacci 38.2% 57.89
52-Week Low 37.44

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar